

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential thrombocythemia | D013920 | — | D47.3 | — | — | 3 | — | — | 3 |
| Polycythemia vera | D011087 | — | D45 | — | — | 1 | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Bomedemstat |
| INN | bomedemstat |
| Description | Bomedmestat (USAN; IUPAC name N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide) is an investigational drug under development by Imago BioSciences for the treatment of myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera and myelofibrosis.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C(=O)[C@H](CCCN[C@@H]2C[C@H]2c2ccc(F)cc2)NC(=O)c2ccc(-n3ccnn3)cc2)CC1 |
| PDB | — |
| CAS-ID | 1990504-34-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297289 |
| ChEBI ID | — |
| PubChem CID | 122460381 |
| DrugBank | DB15126 |
| UNII ID | Y2T4ALDEAT (ChemIDplus, GSRS) |
